Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE)
Authors
Keywords
-
Journal
Multiple Sclerosis Journal
Volume -, Issue -, Pages -
Publisher
SAGE Publications
Online
2023-06-15
DOI
10.1177/13524585231175284
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ocrelizumab: A Review in Multiple Sclerosis
- (2022) Yvette N. Lamb DRUGS
- Use of natalizumab in persons with multiple sclerosis: 2022 update
- (2022) Sarah A. Morrow et al. Multiple Sclerosis and Related Disorders
- Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment
- (2021) Susana Otero-Romero et al. Expert Review of Clinical Immunology
- Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
- (2021) Aurora Zanghì et al. Neurotherapeutics
- PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study
- (2021) Clara G. Chisari et al. JOURNAL OF NEUROLOGY
- Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
- (2021) Stephen L Hauser et al. NEUROLOGY
- Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis
- (2021) Shitiz Sriwastava et al. JOURNAL OF NEUROIMMUNOLOGY
- Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
- (2020) Helmut Butzkueven et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
- (2020) Kathy Khoy et al. Frontiers in Immunology
- Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
- (2019) Frederik Barkhof et al. NEUROLOGY
- Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)
- (2018) Stanley L. Cohan et al. Multiple Sclerosis and Related Disorders
- Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis
- (2018) Y. Naegelin et al. Multiple Sclerosis and Related Disorders
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
- (2017) Pei-Ran Ho et al. LANCET NEUROLOGY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Aging and multiple sclerosis
- (2016) Shaik Ahmed Sanai et al. Multiple Sclerosis Journal
- Aging and multiple sclerosis
- (2016) Shaik Ahmed Sanai et al. Multiple Sclerosis Journal
- MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
- (2014) R. J. Fox et al. NEUROLOGY
- Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
- (2014) Marinella Clerico et al. JAMA Neurology
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Anti-JC virus antibodies: Implications for PML Risk Stratification
- (2010) Leonid Gorelik et al. ANNALS OF NEUROLOGY
- Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
- (2010) Augusto Miravalle et al. ARCHIVES OF NEUROLOGY
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
- (2009) Eva Havrdova et al. LANCET NEUROLOGY
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
- (2008) Erik von Elm et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started